SCLP – Scancell Holdings Plc
Scancell Holdings (LSE:SCLP), the Oxford- and Nottingham-based cancer immunotherapy developer, has moved to solve the problem that dogs almost every clinical-stage biotech: how to pay for a pivotal trial. On 23 July 2026 the AIM-quoted group unveiled an all-share merger with Nasdaq-listed Neuphoria Therapeutics, packaged alongside a financing of up to $89 million. The combination is designed to bankroll a registrational Phase 3 study of its lead melanoma candidate, iSCIB1+, and to give the enlarged company a US listing to sit beside its London quotation.
The deal follows a run of clinical momentum. In late April the US Food and Drug Administration awarded iSCIB1+ Fast Track designation in advanced melanoma, a status that can speed regulatory interaction and review. Taken together, the two events reframe the investment case: Scancell now has both a regulatory tailwind and, if the transaction completes, a funded path towards a late-stage readout.
Company background
Scancell (LSE:SCLP) develops immunotherapies built around three proprietary platforms. Its ImmunoBody DNA vaccines, which include iSCIB1+ and the earlier SCIB1, are designed to stimulate high-avidity T-cell responses against tumour antigens. The Moditope platform targets stress-induced modified proteins and underpins Modi-1, while the GlyMab programme generates antibodies against tumour-associated glycans, an area that has drawn a research collaboration with Genmab.
The company has long positioned melanoma as its lead indication, using needle-free delivery of its DNA constructs alongside standard checkpoint inhibitors rather than in place of them. That combination approach is central to the data now underpinning the Phase 3 ambition.
The merger behind the headline
Under the agreement, Scancell will acquire Neuphoria in an all-share transaction, with the combined business continuing under the Scancell name. It intends to add a Nasdaq listing under the ticker SCLT while retaining its AIM quotation as SCLP. The exchange ratio is set at roughly 37.77 Scancell American Depositary Shares per Neuphoria common share, equating to around 204.1 million consideration shares, or about 20.4 million ADSs.
On a pro forma basis, existing Scancell shareholders are expected to hold approximately 85.5% of the enlarged group and Neuphoria stockholders about 14.5%, a split that shifts slightly once new financing is layered in. Neuphoria holders are also to receive contingent value rights tied to that company's partnered assets. Both boards have approved the transaction, which management expects to complete in late Q4 2026, subject to shareholder votes and regulatory clearances.
Financing and the numbers
The up-to-$89 million package is assembled from several strands: a $39.1 million private placement from new and existing investors, a UK placing of roughly $12 million, a retail offer of up to $3 million, up to $25 million of debt via funds managed by BlackRock under a non-binding term sheet, and a minimum $10 million of cash carried in from Neuphoria. Management points to pro forma net cash of around $79.1 million on completion.
Crucially, the company frames this as enough to carry the Phase 3 trial through to its primary readout in the second half of 2028 and to extend the group's cash runway into 2029. For a business that has historically financed itself in shorter increments, that is a marked lengthening of visibility.
Recent results and comparatives
The financing arrives against a tightening balance sheet. In interim results for the six months to 31 October 2025, Scancell reported cash of £8.6 million, down from £16.9 million at the 30 April 2025 year-end, with a further £3.0 million of R&D tax credits received in December 2025. At the time, management guided to a runway extending into H2 2026 — a horizon the merger is intended to push well beyond.
Operating performance showed tighter cost control. The operating loss for the half narrowed to £8.9 million from £10.5 million a year earlier, with R&D spend easing to £6.1 million from £8.0 million as manufacturing costs fell. The net loss after tax came in at £5.7 million, against £12.5 million in the prior-year period, though the group reported net liabilities of £8.4 million and roughly £18.2 million of convertible notes falling due in 2027. On our reading, the deal addresses funding but does not remove the near-term maturities that will need managing.
Fast Track and the SCOPE data
The clinical foundation for all of this is the SCOPE Phase 2 study (NCT04079166), an open-label trial combining Scancell's vaccines with checkpoint therapy in advanced melanoma. Announcing Fast Track on 28 April 2026, the company reported 77% progression-free survival at 20 months in a target population defined by HLA alleles present in about 80% of melanoma patients. Management framed that as a 30-plus percentage point improvement over the roughly 43% seen with ipilimumab plus nivolumab alone at the same timepoint, though such cross-comparisons are not head-to-head.
Fast Track designation itself confers more frequent FDA engagement and potential eligibility for accelerated review, but it is a procedural status, not evidence of efficacy or a guarantee of approval. Further PFS and early overall survival data are expected in the first half of 2027.
Strategy and growth drivers
The strategic logic is straightforward. A Nasdaq listing broadens access to specialist US healthcare investors, the natural funding pool for a company pursuing a registrational oncology trial, while the financing removes the immediate question of how the Phase 3 gets paid for. Beyond iSCIB1+, optionality remains in Modi-1, where data from the ModiFY study in head-and-neck and renal cancers has been anticipated, and in the GlyMab antibody work linked to Genmab.
The nearer-term value driver, however, is clearly the melanoma programme, with a Phase 3 initiation anticipated in the second half of 2026.
Competitive context
Melanoma is among the most crowded and best-served solid-tumour markets in immuno-oncology, dominated by checkpoint inhibitors from the largest pharmaceutical companies. Scancell's pitch is additive rather than confrontational: a vaccine layered on top of existing standards of care to deepen and prolong responses. That positioning could ease adoption if the data hold, but it also means the candidate's commercial case rests on demonstrating clear incremental benefit over regimens that are already effective and entrenched. The therapeutic-cancer-vaccine field, meanwhile, has a long history of high-profile late-stage disappointments.
Key risks
The risks are considerable. The transaction is conditional on shareholder approvals and regulatory clearances and could be delayed or fail to complete. Part of the debt element rests on a non-binding term sheet, so the headline $89 million is a ceiling rather than committed capital in full. Existing shareholders face dilution from the placing and merger, and the enlarged share count is substantial.
On the science, a single-arm Phase 2 signal, however encouraging, must still be confirmed in a randomised registrational setting, and biotech history is littered with mid-stage results that did not replicate. The 2027 convertible maturities and the interim net-liability position add balance-sheet risk that the financing softens but does not entirely dispel.
Milestones to watch
Investors have several concrete markers ahead. The most immediate are completion of the Neuphoria merger and associated financing, expected in late Q4 2026, and the anticipated start of the iSCIB1+ Phase 3 trial in the second half of 2026. Further SCOPE PFS and early overall survival data are due in the first half of 2027, with the pivotal trial's primary readout guided for the second half of 2028. Progress on Modi-1 and any developments in the GlyMab antibody collaboration provide secondary catalysts.
Conclusion
The Neuphoria merger and financing, arriving on the back of Fast Track designation, mark one of the more consequential steps in Scancell's history: a potential dual listing, a multi-year runway and a clearer route to a late-stage melanoma readout. Set against that are execution risk on the deal, dilution, a still-strained balance sheet and the fundamental uncertainty of confirming Phase 2 promise in Phase 3.
On our reading, Scancell has converted a funding overhang into a defined, if demanding, plan. Whether that translates into value now hinges on completion of the transaction and, ultimately, on data the company will not report for some time yet.






Please wait processing your request...